Literature DB >> 8036010

Oncostatin M activates phosphatidylinositol-3-kinase in Kaposi's sarcoma cells.

R Soldi1, A Graziani, R Benelli, D Ghigo, A Bosia, A Albini, F Bussolino.   

Abstract

Oncostatin M (OM) is a polypeptide cytokine that induces autocrine and paracrine effects on AIDS-Kaposi's sarcoma (KS) cells (Nair et al., Science, 255, 1430-1432, 1992; Miles et al., Science, 255, 1432-1434, 1992). The signalling pathways underlying this activation are largely unknown. We have found that OM binding to KS cell lines in vitro identifies a higher affinity binding site (Kd 10-20 pM) with a lower affinity (Kd 1.5 nM), high capacity binding site. The binding of OM to its receptor at the KS cell surface stimulates a rapid tyrosine phosphorylation of multiple proteins, including the p85 regulatory subunit of phosphatidylinositol-3-kinase (PI3K). In addition OM can stimulate the in vivo activation of PI3K and increases the PI3K activity in anti-phosphotyrosine and anti-src kinase family antibody directed immunoprecipitates. Genistein, an inhibitor of tyrosine kinases, inhibits the synthesis of phosphatidylinositol 3,4-biphosphate and the growth of KS cells. Finally, OM enhances tyrosine kinase activity in immune complex kinase assay performed with antibody anti-src kinase family. These data suggest that in KS cells OM can stimulate formation of tyrosine kinase co-ordinate signalling complexes, containing at least src kinase family and PI3K, which can drive the accumulation of the putative second-messengers D3-phosphorylated phosphoinositides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036010

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

2.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

3.  Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.

Authors:  R Soldi; S Mitola; M Strasly; P Defilippi; G Tarone; F Bussolino
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

Review 4.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

5.  PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma.

Authors:  Mohammad Firoozinia; Mohammad Zareian Jahromi; Soheil Zorofchian Moghadamtousi; Sonia Nikzad; Habsah Abdul Kadir
Journal:  Int J Med Sci       Date:  2014-04-22       Impact factor: 3.738

6.  CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways.

Authors:  Cheng-Yu Chen; Chen-Ming Su; Yuan-Li Huang; Chun-Hao Tsai; Lih-Jyh Fuh; Chih-Hsin Tang
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.